The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 653-656

  Van Der Wilt, C L ^a   Smid, K ^a   Veerman, G ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALIA; MURINAE;

EID: 0031836654     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_126     Document Type: Conference Paper

References (13)

1. Pinedo HM, Peters GJ. Fluorouracil, biochemistry and pharmacology. J Clin Oncol 1988, 6:1653-1664
2. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Meyer S, Pinedo HM. Thymidiylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J Clin Oncol 1994, 12:2035-2042
3. Nord LD, Martin DS. Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. Biochem Pharmacol 1991, 12:2369-2375
4. Van Laar JAM, Rustum YR, Van der Wilt CL, Smid K, Pinedo HM, Peters GJ. Tumor size and origin determine antitumor activity of ciplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Cancer Chemother Pharmacol 1996, 39:79-89
5. Houghton JA, Williams LG, Loftin SK, Cheshire PJ, Morton CL, Houghton PJ, Dayan A, Jolivet J. Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 1992-30:423-432
6. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994 140:1-22
7. Ruiz van Haperen VWT, Veerman G, Van Moorsei CJA, Peters GJ. Induction of in vivo resistance against gemcitabine (gem, 2′,2′-difluorodeoxycytidine). This volume
8. Ruiz van Haperen VWT, Veerman G, Erikson S, Boven E, Stegmann APA, Hermsen M, Vermerken JB, Pinedo HM, Peters GJ. Development and molecular characterization of a-2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994 54:43-138-4143
9. Van der Wilt CL, Pinedo HM, Smid K, Cloos J, Noordhuis P, Peters GJ. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase. Sem Oncol 1992 19(suppl 2):16-25
10. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase levels following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992 52:4922-4928
11. Kralovanski J, Prajda N, Kerpel-Fronius S, Bagrij T, Kiss E, Peters GJ. Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high dose uridine. Cancer Chemother. Pharmacol. 1993, 32:243-248
12. Damowski J, Goulette F.A. Increased azidodeoxythymidine metabolism in the presence of fluorouracil reflects increased thymidine kinase activity. Proc Amer Ass Cancer Res 1993 34:302
13. Pressacco J, Mitrovskt B, Erlichman C, Hedley D. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995-55:1505-1508